Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

References

• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2009 (Vintage 2009 populations) Available from: http://seer.cancer.gov/csr/1975_2009_pops09/Accessed September 24, 2012
   Google Scholar
• American Cancer SocietyCancer Facts and Figures 2013Atlanta, GA, USAAmerican Cancer Society2013 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdfAccessed November 26, 2013
   Google Scholar
• BinetJLAuquierADighieroGA new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer19814811982067237385
   PubMed Web of Science ®Google Scholar
• LeoniLMBaileyBReifertJBendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin Cancer Res200814130931718172283
   PubMed Web of Science ®Google Scholar
• StrumbergDHarstrickADollKBendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesAnticancer Drugs1996744154218826610
   PubMed Web of Science ®Google Scholar
• KnaufWLissichkovTAldaoudAPhase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol200927264378438419652068
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol200725355616562317984186
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRStilgenbauerSFirst-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood2009114163382339119605849
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNational Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphoma32012 Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdfAccessed on July 13, 2012
   Google Scholar
• ShanafeltTDGundersonHCallTGCommentary: chronic lymphocytic leukemia – the price of progressOncologist201015660160220463087
   PubMed Web of Science ®Google Scholar
• DaneseMGleesonMReyesCCost of chronic lymphocytic leukemia (CLL) in Medicare patientsJ Clin Oncol20082615S17531
   Web of Science ®Google Scholar
• Centers for Medicaid and Medicare ServicesHospital Outpatient PPS Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html?redirect=/HospitalOutpatientPPS/Accessed September 24, 2012
   Google Scholar
• Thomson ReutersRed Book Online Available from: http://www.redbook.com/redbook/online/Accessed September 24, 2012
   Google Scholar
• Centers for Medicaid and Medicare ServicesPhysician Fee Schedule National Payment Amount File2012 Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-National-Payment-Amount-File-Items/PFREV12B.htmlAccessed September 24, 2012
   Google Scholar
• Centers for Medicaid and Medicare Services2012Clinical Diagnostic Laboratory Fee Schedule. National Limit Fee Available from: http://www.cms.gov/apps/ama/license.asp?file=/ClinicalLabFeeSched/downloads/12CLAB.ZIPAccessed September 24, 2012
   Google Scholar
• WalkerSPalmerSErhornSFludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemiaHealth Technol Assess20091313 Suppl 1354019567212
   PubMed Web of Science ®Google Scholar
• GoorKMSchaafsmaMRHuijgensPCvan AgthovenMEconomic assessment on the management of chronic lymphocytic leukaemiaExpert Opin Pharmacother2005671179118915957971
   PubMed Web of Science ®Google Scholar
• MartinSMartyFFiumaraKInfectious complications associated with alemtuzumab use for lymphoproliferative disordersClin Infect Dis2006431162416758413
   PubMed Web of Science ®Google Scholar
• GreenbergDEarleCFangCHEldar-LissaiAWhen is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyJ Natl Cancer Inst20101022828820056956
   PubMed Web of Science ®Google Scholar
• KnaufWULissitchkovTAldaoudABendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trialBr J Haematol20121591677722861163
   PubMed Web of Science ®Google Scholar
• TerasawaTTrikalinosNADjulbegovicBTrkalinosTAComparative efficacy of first-line therapies for advanced-stage chronic lymphyocytic leukemia: a multiple-treatment meta-analysisCancer Treat Rev201339434034922703832
   PubMed Web of Science ®Google Scholar
• VidalLGafter-GviliAGurionRRaananiPDreylingMShpilbergOBendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaCochrane Database Syst Rev20129CD00904522972131
   PubMed Web of Science ®Google Scholar
• CaroJPharmacoeconomic analyses using discrete event simulationPharmacoeconomics200523432333215853433
   PubMed Web of Science ®Google Scholar
• StevensonFKKrysovSDaviesAJSteeleAJPackhamGB-cell receptor signaling in chronic lymphocytic leukemiaBlood2011118164313432021816833
   PubMed Web of Science ®Google Scholar
• AmreinPCAttarECTakvorianTPhase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemiaClin Cancer Res20111792977298621402714
   PubMed Web of Science ®Google Scholar
• McCaigAMCosimoELeachMTMichieAMDasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signalsBr J Haematol2011153219921121352196
   PubMed Web of Science ®Google Scholar
• FischerKCramerPBuschRBendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupJ Clin Oncol201230263209321622869884
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEUK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies GroupNCRI Chronic Lymphocytic Leukaemia Working GroupAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet2007370958323023917658394
   PubMed Web of Science ®Google Scholar